Dr. Bruna Pellini of Baptist Health Miami Cancer Institute joins Healthcare Unfiltered EXPRESS to break down the most important lung cancer data presented at ASCO 2026. Together, we discuss the trials most likely to influence clinical practice, what they mean for patients today, and how they may reshape future treatment decisions. Watch on YouTube, subscribe, share, review, and join the conversation.

Hot off the press, the ENDURANCE trial was JUST published in NEJM. This trial explored whether patients with newly diagnosed myeloma benefit from long-term maintenance lenalidomide versus 2-years only. Dr. Vincent Rajkumar, senior author on the paper, shares the findings and context. Please subscribe, share, and join the conversation.

Dr. Amer Zeidan joins the Healthcare Unfiltered EXPRESS to discuss the recently published KOMET-007 trial, which made its way to print in Blood. Dr. Zeidan discusses how Menin inhibitors are transforming how we approach AML like no other therapies before. What does the future hold and how will the results of this trial affect therapy? The KOMET-007 trial is a Phase 1/2 clinical study evaluating the targeted Menin inhibitor ziftomenib in combination with standard-of-care chemotherapies for acute myeloid leukemia (AML) patients with NPM1 mutations or KMT2A rearrangements.

A must listen - please share subscribe, and join the conversation.